# Explorative studies of novel IgE ligands

> **NIH NIH R21** · STANFORD UNIVERSITY · 2020 · $236,550

## Abstract

Project Summary
Most allergic reactions are caused by immunoglobulin E (IgE) antibodies that are specific for allergens and that
trigger potent inflammatory responses mediated by mast cells and basophils. IgE binds to the high affinity
receptor (FcεRI) expressed on these allergic effector cells, making this a central interaction that is common to
different allergen-specific responses. The anti-IgE antibody (omalizumab) is currently used to treat allergic
asthma and chronic idiopathic urticaria, demonstrating the feasibility of inhibiting the IgE:FcεRI interaction for
therapeutic benefit. We have developed multiple approaches to identifying small molecule ligands for the IgE
and identified promising leads for further studies. In this proposal, we will further investigate these leads to
explore the possibility of producing novel probes for IgE function and inhibition.
!

## Key facts

- **NIH application ID:** 10055790
- **Project number:** 1R21AI144645-01A1
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Theodore S Jardetzky
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $236,550
- **Award type:** 1
- **Project period:** 2020-06-16 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10055790

## Citation

> US National Institutes of Health, RePORTER application 10055790, Explorative studies of novel IgE ligands (1R21AI144645-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10055790. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*